Researchers confirm that pubertal timing in girls is most strongly influenced by that of their mothers, whereas for boys their fathers have the stronger influence.
Levels of dehydroepiandrosterone sulfate at the age of 7 years may determine how soon healthy girls progress to thelarche, pubarche and menarche, say researchers.
Research suggests that a single challenge with the neuropeptide kisspeptin can distinguish between children with pubertal delay who will or will not require long-term gonadotropin-releasing hormone therapy.
Pubertal boys with true gynaecomastia have a significantly higher oestradiol-to-testosterone ratio than those with pseudogynaecomastia or healthy controls, observational study data show.
Our podcast with Dr Sogol Mostoufi, from the Children’s Hospital of Philadelphia in Pennsylvania, USA, focuses on the treatment-related endocrine side effects commonly experienced by childhood cancer survivors, and the need for screening, life-long follow-up and treatment in this high-risk population.
Girls with central precocious puberty or early and fast puberty benefit from the addition of recombinant human growth hormone to gonadotropin-releasing hormone analogues but the combination should not be routinely recommended, researchers report.
Precocious puberty is a prevalent endocrine disorder that affects children globally. Classically, precocious puberty is defined as the development of secondary sexual characteristics before age 8 years in girls and 9 years in boys and it has a clear female predominance.
The European Cooperation in Science and Technology Action DSDnet group have published recommendations for standardised data collection during clinical follow-up of patients with differences of sexual development.
A Swedish study suggests that, as with girls, puberty has shifted to begin at an earlier age in boys.
In our first edition, Professor Frederic Castinetti discussing the results of an international collaboration to study the natural history and treatment outcomes of multiple endocrine neoplasia type 2B, and Professor Martin Savage comments on a randomized trial of letrozole versus testosterone in boys with constitutional delay of growth and puberty.
